For Most Men With Prostate Cancer, Hormone Therapy With Postprostatectomy Radiotherapy Confers No Survival Benefit
Adding hormone therapy to postprostatectomy radiotherapy may provide little survival benefit for most men with prostate cancer, especially those with very low prostate-specific antigen (PSA) levels before treatment. In the study, reported at the 2026 ASCO Genitourinary Cancers Symposium,1 men with low PSA levels prior to postprostatectomy radiotherapy who received either short-term or long-term hormone therapy with radiotherapy derived no survival advantage over postprostatectomy radiotherapy alone. Those with higher pre-radiotherapy PSA levels did see some benefit, however, suggesting that adding hormones in this group might be worthwhile.
New AACR President-Elect and Board Members Announced
The members of the American Association for Cancer Research (AACR) have elected Robert H. Vonderheide, MD, DPhil, as the AACR President-elect for 2026–2027. Dr. Vonderheide will become President-Elect on Monday, April 20, during AACR’s Annual Business Meeting of Members at the AACR Annual Meeting 2026 in San Diego. He will assume the Presidency in April 2027 at the AACR Annual Meeting in Orlando.
AMA Survey Finds Rapid Growth in Physician AI Adoption
The 2026 Physician Survey on Augmented Intelligence from the American Medical Association’s (AMA) Center for Digital Health and AI indicates that physician adoption of AI is increasing alongside growing confidence in the technology’s ability to address clinical challenges.
Breast Cancer: Ultrasensitive ctDNA Assay Findings and Outcomes After Neoadjuvant Therapy
In a study (PREDICT-DNA) reported in the Journal of Clinical Oncology, Hunter et al found that an ultrasensitive assay for circulating tumor DNA (ctDNA) to detect measurable residual disease after neoadjuvant therapy in patients with breast cancer did not distinguish pathologic complete response (pCR) from no pCR, but did provide important prognostic information.
Forgotten Lessons From South Africa
On March 10, 2000, it was a cold Friday morning in Washington, DC. As usual, we the oncology fellows and faculty crowded into a conference room at the NIH Clinical Center in Building 10 for our weekly conference. Before the session formally began, a senior faculty member walked in holding the New York Times, opened to the science section, and read aloud: “Cancer Researcher in South Africa Who Falsified Data Is Fired.”
Charles Bennett and colleagues: The Inflation Reduction Act and Ibrutinib
Derek Raghavan: How I Discuss the Current Political Chaos When Patients Ask Health-Related Questions About It
Narjust Florez and Coral Olazagasti: Silence Is Complicity
Robert Peter Gale: Therapy With a TKI for EGFR-Variant Lung Adenocarcinoma: Lessons From CML?
Raj Mohan on Kindness, Mercy, Empathy, Compassion: Are They Relevant in the Era of Robotics and AI?
Sponsored Content
SPONSORED BY LILLY MEDICAL AFFAIRS
Treatment Considerations for Relapsed/Refractory CLL in the Post-cBTKi SettingMore Top Stories
I’m Young and Have Advanced Neuroendocrine Carcinoma of the Rectum
Eight years ago, I was 33 years old, and my main health concern was a diagnosis of ankylosing spondylitis, a form of arthritis that causes stiff, painful joints in the spine. Having a chronic disease made me pay close attention to any changes in my health, so when I noticed blood in my stool, I...
Tiragolumab/Atezolizumab and Chemotherapy Fails in Advanced Nonsquamous NSCLC
As reported in JAMA Oncology by Socinski et al, the phase III SKYSCRAPER-06 trial showed no progression-free or overall survival benefit with tiragolumab, a monoclonal antibody targeting T-cell immunoreceptor with Ig and ITIM domains (immunoreceptor tyrosine-based inhibitory motifs) (TIGIT), plus...
New ASCO Guideline Fills Gap in Guidance on Rapidly Evolving Treatment Options in Thyroid Cancer
ASCO has issued a new clinical practice guideline on the use of systemic therapy for treatment of different types of thyroid cancer, a field that has changed substantially in recent years.1 “Despite a rather rapidly evolving field of targeted and nontargeted systemic agents in the management of...
Patient Care Is Not What We Do, But What Patients Perceive
MUHAMMAD RAFIQUL ISLAM, MBBS, MD, MSPH, FACP In modern health care, patient care is often defined by clinical actions such as diagnoses made, treatments delivered, and protocols followed. Clinicians are trained to prioritize technical accuracy, evidence-based interventions, and measurable...
Long-Term Outcomes With Maintenance Rucaparib in Advanced Pancreatic Cancer With BRCA or PALB2 Pathogenic Variants
In an analysis of a single-center trial reported in a research letter in JAMA Oncology, Reiss et al identified long-term outcomes with rucaparib maintenance in patients with platinum-sensitive advanced pancreatic ductal adenocarcinoma (PDAC) with BRCA1, BRCA2, or PALB2 germline or somatic...
Gerald Hsu, MD, PhD, Named Editor-in-Chief of the ASCO Educational Book
ASCO is pleased to announce the appointment of Gerald Hsu, MD, PhD, as the new Editor-in-Chief of the ASCO Educational Book. Dr. Hsu is a Professor of Clinical Medicine at the University of California, San Francisco (UCSF), where he has served in numerous educational leadership roles. Since 2018,...
Appendiceal Cancer: Serum Tumor Marker Levels May Guide Treatment in Patients Undergoing Cytoreductive Surgery
A retrospective study found that levels of commonly measured serum tumor markers—CEA, CA19-9, and CA125—can play a significant role in predicting outcomes in patients with appendiceal adenocarcinoma undergoing cytoreductive surgery (CRS), with or without hyperthermic intraperitoneal chemotherapy...
